CASCADES INC.
Institutional Investor Roadshow – Montreal & Toronto
March 22 - 23, 2017
Certain statements in this presentation, including statements regarding future results and performance, are forward-looking statements within the meaning of securities legislation based on current expectations. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those projected, including, but not limited to, the effect of general economic conditions, decreases in demand for Cascades Inc.’s (“Cascades,” “CAS,” the “Company,” the “Corporation,” “us” or “we”) products, the prices and availability of raw materials, changes in the relative values of certain currencies, fluctuations in selling prices and adverse changes in general market and industry conditions. This presentation may also include price indices as well as variance and sensitivity analyses that are intended to provide the reader with a better understanding of the trends related to our business activities. These items are based on the best estimates available to the Company.

The financial information included in this presentation also contains certain data that are not measures of performance under IFRS (“non-IFRS measures”). For example, the Company uses operating income before depreciation and amortization (“OIBD or EBITDA”) and adjusted operating income before depreciation and amortization (“adjusted OIBD or adjusted EBITDA”) because such measures are used by management to assess the operating and financial performance of the Company’s operating segments. Such information is reconciled to the most directly comparable financial measures, as set forth in the “Supplemental Information on Non-IFRS Measures” section of our most recent quarterly report or annual report.

Adjusted measures exclude specific items. Specific items are defined as items such as charges for or reversal of impairment of assets, for facility or machine closures, accelerated depreciation of assets due to restructuring measures, premiums paid on long-term debt refinancing, loss on refinancing of long-term debt, gains or losses on sales of business units, unrealized gains or losses on derivative financial instruments that do not qualify for hedge accounting, unrealized gains or losses on interest rate swaps, foreign exchange gains or losses on long-term debt, other significant items of an unusual or non-recurring nature, and all such items included in discontinued operations or in the share of results of our associates and joint ventures.

All amounts in this presentation are in Canadian dollars unless otherwise indicated.
COMPANY OVERVIEW

- Founded in 1964 by the Lemaire family; headquartered in Kingsey Falls, QC
- Produces, converts and markets packaging & tissue products composed principally of recycled fibres
  - Balanced play in less cyclical sectors
  - Good presence in two of the strongest paper segments: Tissue and Containerboard
  - Market leader across many of its primary product offerings
- Unique culture – green visionaries, turnarounds, entrepreneurial philosophy
- ~ 90 facilities in Canada, US & Europe
- ~ 11,000 employees worldwide

2016 Net Sales $4,001 million

Segment Sales Breakdown
- Containerboard: 34%
- Tissue Papers: 32%
- Boxboard Europe: 19%
- Specialty Products: 15%

2016 Adjusted EBITDA $403 million

Segment Adjusted EBITDA Breakdown
- Containerboard: 45%
- Tissue Papers: 31%
- Boxboard Europe: 11%
- Specialty Products: 13%

1 Before inter-segment sales and corporate activities
2 Including joint ventures
3 Via our 57.7% equity ownership in Reno de Medici S.p.A. (RdM)
## COMPANY OVERVIEW

### 2016 Key Performance Indicators

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shipments (‘000 s.t.)</td>
<td>2,999</td>
</tr>
<tr>
<td>Containerboard integration rate</td>
<td>67%(^1)</td>
</tr>
<tr>
<td>Tissue paper integration rate</td>
<td>68%</td>
</tr>
<tr>
<td>Adjusted EBITDA margin</td>
<td>10.1%</td>
</tr>
<tr>
<td>Return on capital employed</td>
<td>5.2%</td>
</tr>
<tr>
<td>Working capital (% of sales)</td>
<td>11.0%</td>
</tr>
<tr>
<td>Net debt/Adjusted EBITDA</td>
<td>3.8x</td>
</tr>
</tbody>
</table>

\(^1\) Including associates and joint ventures

### 2016 Revenue Profile

#### Sales To (Destination)
- **Canada**: 39%
- **U.S.**: 39%
- **Europe**: 22%

#### Sales From (Source)
- **Canada**: 51%
- **U.S.**: 28%
- **Europe**: 21%
OPERATING PERFORMANCE AND FINANCIAL SITUATION
Strong Financial Momentum

**Sales**

- CAGR: 6.2%

**Adjusted EBITDA**

- CAGR: 9.0%

-$3$ million EBITDA sensitivity to every US$0.01 change vs CAN$

Steady sales growth since 2012; Adjusted EBITDA remained strong in 2016 despite lower year-over-year results
OPERATING PERFORMANCE AND FINANCIAL SITUATION

Adjusted Cash Flow and Free Cash Flow per Share

Adjusted Cash Flow From Operating Activities

<table>
<thead>
<tr>
<th>Year</th>
<th>Adjusted Cash Flow (M CAN$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>155</td>
</tr>
<tr>
<td>2013</td>
<td>233</td>
</tr>
<tr>
<td>2014</td>
<td>277</td>
</tr>
<tr>
<td>2015</td>
<td>337</td>
</tr>
<tr>
<td>2016</td>
<td>324</td>
</tr>
</tbody>
</table>

CAGR: 20.2%

Adjusted Free Cash Flow\(^1\) per Share

<table>
<thead>
<tr>
<th>Year</th>
<th>Adjusted Free Cash Flow (CAN$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>($0.28)</td>
</tr>
<tr>
<td>2013</td>
<td>$0.78</td>
</tr>
<tr>
<td>2014</td>
<td>$0.86</td>
</tr>
<tr>
<td>2015</td>
<td>$1.58</td>
</tr>
<tr>
<td>2016</td>
<td>$1.20</td>
</tr>
</tbody>
</table>

- Cash flows have grown at a 20% CAGR since 2012
- Improving cash flows driven by Strategic Action Plan

Objective: Direct ~$100M of free cash flow annually toward debt reduction

\(^1\) Adjusted free cash flow defined as adjusted operating cash flow less capital expenditures, capital lease and dividend payments, but excluding increases in investments.
Over last 36 months, $1 billion+ of senior notes refinanced
  - Extended maturities to 2021, 2022 and 2023
  - $750 million revolving facility extended to 2019
  - Average interest rate down 84 bps to 5.21% in 2016 from 6.05% in 2013
  - Translates into annual interest savings of ~ $11 million
Leverage ratio of 3.1x at year-end 2016 if the current market value of investment in Boralex is removed from net debt

1 Based on Street's adjusted EBITDA estimates $445 million for 2017 and $470 million for 2018. Assuming stable adjusted EBITDA for 2019 ($470 million), FX US$/CAN$ at 1.30 and only $100 million of free cash flows dedicated to debt annually.

2 Based on BLX March 20, 2017 closing price on the TSX of $20.75.
OPERATING PERFORMANCE AND FINANCIAL SITUATION
Historical Segmented Adjusted EBITDA and Margin

Containerboard

2012 – 2016 CAGR: 24%

2012
2013
2014
2015
2016

50
100
150
200
250
300

(M CAN$)

Boxboard Europe¹

2012 – 2016 CAGR: 5%

2012
2013
2014
2015
2016

0
20
40
60
80
100

(M CAN$)

Specialty Products

2012 – 2016 CAGR: 15%

2012
2013
2014
2015
2016

37
41
40
58
65

(M CAN$)

Tissue Papers

2012 – 2016 CAGR: 2%

2012
2013
2014
2015
2016

43
57
72
63
53

(M CAN$)

¹ Via our 57.7% equity ownership in Reno de Medici S.p.A. (RdM)
² Including $9 million of energy credits
## Division Leaders & Sales by Country

<table>
<thead>
<tr>
<th>Containerboard</th>
<th>Boxboard Europe&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Specialty Products</th>
<th>Tissue Papers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A Canadian leader</strong>&lt;sup&gt;2&lt;/sup&gt;</td>
<td><strong>#2 producer of coated recycled boxboard in Europe</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>Largest paper collector in Canada</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>A Canadian leader</strong>&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Charles Malo President &amp; COO</td>
<td>Michele Bianchi President &amp; CEO</td>
<td>Luc Langevin President &amp; COO</td>
<td>Jean Jobin President &amp; COO</td>
</tr>
<tr>
<td>26 years with Cascades</td>
<td>With Reno de Medici since 2016</td>
<td>21 years with Cascades</td>
<td>24 years with Cascades</td>
</tr>
<tr>
<td><strong>34% of Sales</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>19% of Sales</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>15% of Sales</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>32% of Sales</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>45% of Adjusted EBITDA</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>11% of Adjusted EBITDA</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>13% of Adjusted EBITDA</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td><strong>31% of Adjusted EBITDA</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

### Sales by Region

<table>
<thead>
<tr>
<th>Containerboard</th>
<th>Boxboard Europe&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Specialty Products</th>
<th>Tissue Papers</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>28%</td>
<td>38%</td>
<td>75%</td>
</tr>
<tr>
<td>Canada</td>
<td>71%</td>
<td>53%</td>
<td>25%</td>
</tr>
<tr>
<td>Other</td>
<td>10%</td>
<td>9%</td>
<td>25%</td>
</tr>
<tr>
<td><strong>2016 sales</strong></td>
<td><strong>$1,370M</strong></td>
<td><strong>$796M</strong></td>
<td><strong>$620M</strong></td>
</tr>
</tbody>
</table>

---

<sup>1</sup> Via our 57.7% equity ownership in Reno de Medici S.p.A. (RdM)
<sup>2</sup> Including 100% of Greenpac’s capacity
<sup>3</sup> 2016 results; before inter-segment sales and corporate activities
CONTAINERBOARD PACKAGING GROUP
A Leading Canadian and Major North American Player

- Largest corrugated boxes producer in Canada with ~32% market share
- 67% integration rate, targeting 85% in the mid-term
- Strong platforms in Ontario and Québec
- Growing presence in U.S. Northeast

2016 adjusted EBITDA margin of 16%

1 Including associates and joint ventures
**CONTAINERBOARD PACKAGING GROUP**

**Greenpac Mill**

- Largest recycled linerboard mill in NA: 1,500 st/day of recycled linerboard (26 pounds)
- State-of-the-art equipment
- Product differentiation: Greenpac XP grades represented 83% of total production in Q4/16
- Take-or-pay agreement for 81% of the mill’s output
- Cascades’ ownership = 59.7%
  - Partners include a pension fund and two independent converters

Note: Greenpac is not consolidated in results, Cascades does not have effective control under IFRS.

---

Greenpac Production

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(s.t./day)</td>
<td>(s.t./day)</td>
<td>(s.t./day)</td>
<td>(s.t./day)</td>
<td>(s.t./day)</td>
<td>(s.t./day)</td>
<td>(s.t./day)</td>
</tr>
<tr>
<td>1,500</td>
<td>1,400</td>
<td>1,500</td>
<td>1,600</td>
<td>1,700</td>
<td>1,800</td>
<td>1,900</td>
</tr>
</tbody>
</table>

: daily capacity on XP Grades = 1,425 s.t.
CONTAINERBOARD PACKAGING GROUP
Environment Still Sound

North American Containerboard Producers

<table>
<thead>
<tr>
<th>2016 Industry Participants</th>
<th>Industry Operating Rates and Expected Capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of total capacity</td>
<td>(Operating rate)</td>
</tr>
<tr>
<td>IP</td>
<td>33%</td>
</tr>
<tr>
<td>WestRock</td>
<td>19%</td>
</tr>
<tr>
<td>GP</td>
<td>10%</td>
</tr>
<tr>
<td>PCA</td>
<td>9%</td>
</tr>
<tr>
<td>Kapstone</td>
<td>4%</td>
</tr>
<tr>
<td>Cascades¹</td>
<td>4%</td>
</tr>
<tr>
<td>Pratt</td>
<td>4%</td>
</tr>
<tr>
<td>Others</td>
<td>17%</td>
</tr>
<tr>
<td><strong>Top-5 Producers</strong></td>
<td><strong>75%</strong></td>
</tr>
</tbody>
</table>

Fundamentals Sound Despite Added Capacity

- Cascades adjusted EBITDA increases ~$2.5M with every 1% increase in our utilization rate

<table>
<thead>
<tr>
<th>2014 New capacity (+2.3%)</th>
<th>2015 New capacity (+1.2%)</th>
<th>2016e New capacity (+1.2%)</th>
<th>2017e New capacity (+1.7%)</th>
<th>2018e New capacity (+1.7%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>39.8</td>
<td>40.7</td>
<td>41.2</td>
<td>41.7</td>
<td>42.4</td>
</tr>
</tbody>
</table>

Source: RISI, Deutsche Bank, Company reports and estimates

¹ Including 59.7% of Greenpac’s total capacity
² New capacity, net of capacity shutdowns
CONTAINERBOARD PACKAGING GROUP
Business Drivers

Containerboard Benchmark Market Prices

Brown Grades Recycled Fibre Prices

Containerboard price increase announced for March 2017

OCC up US $70 / s.t. since January 2017 due to strong domestic and foreign demand

Source: RISI
BOXBOARD EUROPE GROUP
Second Largest Coated Recycled Boxboard Producer in Europe

- 57.7% equity ownership of Reno de Medici, a public Italian company; 5 recycled (885K m.t.) & 1 virgin boxboard (165K m.t.) mills
- Operations in Italy, France and Germany
- Improved performance by simplifying structure and investments in modernization
- Completed legal transfer of Cascades’ virgin mill in France to RdM in Q2-2016

2016 adjusted EBITDA margin of 7%

Steady contributor to our results

Sales 2016: $796M

Graph showing Sales, Adj. EBITDA, and Adj. EBITDA Margin from 2012 to 2016.
SPECIALTY PRODUCTS GROUP
A Diversified Packaging Player

- A leading position in industrial packaging with Cascades Sonoco JV
- Largest paper collector in Canada with 19 facilities and 1.4 million s.t. of material processed in 2016
- Strong growth potential in consumer packaging
- 2016 sales (IFRS) of $620M, vs. $819M (Non-IFRS) with JVs at 100%

2016 adjusted EBITDA margin of 10%

Focusing on growth sectors

![Chart showing sales and EBITDA growth from 2012 to 2016]
SPECIALTY PRODUCTS GROUP
Cascades Recovery+ Sub-Segment

- Newly formed business unit created via the merger of recovery operations & recycled fibre buying group
- Manages procurement of all raw material fibre for Cascades’ North American operations
  - ✓ 1.2M\(^1\) st of recycled fibre purchased externally (68% brown, 23% white, 9% groundwood)
  - ✓ 1.4M\(^1\) st of recycled fibre collected via 19 recovery centers across Canada and the NE U.S.
  - ✓ 62% of the 2.6M st of recycled fibre that is collected & purchased is used in our NA manufacturing facilities, while remaining 38% is sold to external customers

\(^1\) Figures for FY 2016
TISSUE PAPERS GROUP
A Canadian Leader and Important North American Player

- 5th largest tissue producer in NA based on capacity
- Growing footprint in Western U.S.
- 68% integration rate, targeting 85% in the mid-term
- Repositioned and rebranded Away-from-Home product lines under Cascades PRO brand to simplify product offering
- Launched new Cascades consumer tissue paper lines in Canada: Fluff™ and Tuff™ brands

2016 adjusted EBITDA margin of **11%**

Targeting **13% EBITDA margin short term**
Tissue Pappers Group
Strong Position Across the North American Tissue Market

CAS Sales by Country (2016)

Canada (25%)
- Branded: 43%
  - Private Label: 57%
  - At-Home: 58%
- Away-from-Home: 42%

US (75%)
- Branded: 27%
  - Private Label: 73%
  - At-Home: 53%
- Away-from-Home: 47%

CAS North American Sales by End Markets (2016)

At-Home (46%)
- Branded: 9%
  - Private label: 91%
- Private label: 59%
  - At-Home: 41%

Away-from-Home (37%)
- Branded: 59%
  - Private label: 41%
- Recycled: 67%
  - Virgin: 33%

Parent rolls (17%)
- Branded: 27%
  - Away-from-Home: 47%

Tissue Market Demand

Indexed U.S. Tissue Demand

Historical CAGR 1.8%

North American Tissue Capacity Additions

Index U.S. Tissue Demand

CAGR 1.8%

Source: RISI

1 Source: RISI
TISSUE PAPERS GROUP
Investing for the Future: New Converting Facility in Oregon

• Expands tissue footprint on US West Coast
• $46M invested to date
• 40% integration with St. Helens, OR tissue paper plant, located ~12 km away
• State-of-the-art facility, with annual production capacity of 5.2 M cases or ~ 58,000 s.t. of finished product

• Manufactures virgin & recycled bathroom tissue products and paper hand towels for the US AfH market
• 3 production lines:
  ✓ Line 1: producing
  ✓ Line 2: almost ready for production
  ✓ Line 3: in transit to facility
## TISSUE PAPERS GROUP
Diversified Capacity and Positioning

### 2016 NORTH AMERICAN TISSUE MANUFACTURERS

<table>
<thead>
<tr>
<th>Rank</th>
<th>Company</th>
<th>Capacity ('000 s.t.)</th>
<th>Market Share</th>
<th>Capacity Retail</th>
<th>Capacity AfH</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Georgia-Pacific</td>
<td>2,849</td>
<td>29%</td>
<td>67%</td>
<td>33%</td>
</tr>
<tr>
<td>2</td>
<td>Procter &amp; Gamble</td>
<td>1,494</td>
<td>15%</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>3</td>
<td>Kimberly-Clark</td>
<td>1,466</td>
<td>15%</td>
<td>67%</td>
<td>33%</td>
</tr>
<tr>
<td>4</td>
<td>SCA Tissue NA</td>
<td>784</td>
<td>8%</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td>5</td>
<td><strong>Cascades Tissue</strong></td>
<td><strong>650</strong></td>
<td><strong>7%</strong></td>
<td><strong>62%</strong></td>
<td><strong>38%</strong></td>
</tr>
<tr>
<td>6</td>
<td>Clearwater Paper</td>
<td>435</td>
<td>4%</td>
<td>90%</td>
<td>10%</td>
</tr>
<tr>
<td>7</td>
<td>KP Tissue</td>
<td>400</td>
<td>4%</td>
<td>77%</td>
<td>23%</td>
</tr>
<tr>
<td>8</td>
<td>First Quality Tissue</td>
<td>319</td>
<td>3%</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>9</td>
<td>Irving Tissue</td>
<td>282</td>
<td>3%</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>10</td>
<td>ST Paper &amp; Tissue</td>
<td>160</td>
<td>2%</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>1,044</td>
<td>10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TOTAL</strong></td>
<td><strong>9,883</strong></td>
<td><strong>100%</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: RISI
After years of volatility, parent roll prices have remained relatively stable since 2015.

The recent increase is partially due to lower levels of material generation.
STRATEGIC PRIORITIES & OUTLOOK
STRATEGIC PRIORITY: MODERNIZE
Modernize Core Operations Through Focused Investments

- 2017 Capex ~ $200M
  - Mainly growth Capex
  - Mostly in the US
- Strong free cash flow has funded Capex
- Impacted by strong US$
- Investments made in Tissue Papers (2013-15) and in Containerboard (2012-13) are bearing fruit
- Important IT modernization

Capital Expenditures

<table>
<thead>
<tr>
<th>Year</th>
<th>Containerboard</th>
<th>Boxboard Europe</th>
<th>Specialty Products</th>
<th>Tissue Papers</th>
<th>Corporate &amp; IT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>$184M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>$161M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>$184M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>$206M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>$200M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
STRATEGIC PRIORITY: OPTIMIZE
Optimize Capital Allocation and Reduce Working Capital

Working Capital

% of sales
16%

14.4%
14%
13.5%
12.9%
12.7%
12.3%
11.6%
11.3%
11.4%
11.0%
10%
Q4 2012
Q2 2013
Q4 2013
Q2 2014
Q4 2014
Q2 2015
Q4 2015
Q2 2016
Q4 2016

ONE Cascades, delivering results

Capturing savings through:
- Shared Services
- Supply Chain
- Logistics
- Operational Efficiency
- Human Resources

• Working Capital reduced by ~3.5% = $125M+
• Strategic initiatives generating results
From 2011 to 2016:
- 16 closures
- 6 asset sales

Data on Asset Sales and Closures\(^1\)

- Workforce reduction: – 2,350
- Sales: – $1,045M
- Adjusted EBITDA: – $19M
- Adjusted EBITDA Margin: 2%

- Dopaco division also divested in 2011 to finance Greenpac, Reno and Papersource investments
STRATEGIC PRIORITY: INNOVATE
Innovate to Improve & Develop Processes and Products

OUR OBJECTIVE: 20% of sales from innovative products
Between 2011 and 2016, closed 16 non-performing assets, exited some industries and consolidated many operational platforms in NA, representing ~$1B in sales with marginal 2% adjusted EBITDA margin.
POSITIONING FOR GROWTH
Roadmap to 15% EBITDA Margin

$403M adj. EBITDA & 10% adj. EBITDA Margin

15% EBITDA Margin

- Strategic growth actions through both investments and M&A
- Financial benefits from ONE Cascades & reduction of costs associated with implementation

1. Advanced ONE Cascades initiatives
2. New tissue converting facility in Oregon
3. Benefits from recent strategic restructuring, optimizing & modernizing actions
4. Greenpac consolidation
POSITIONING FOR GROWTH
Disciplined Capital Allocation Strategy

Cash Flow from Operations

Invest in our Asset Base
- Continue to modernize our equipment & infrastructure
- Opportunistic M&A in line with operational & segment growth strategies
- Maximize effectiveness of our geographic footprint in Tissue & Containerboard
- Increase integration rates in Tissue & Containerboard

Debt Reduction
- Objective to allocate at least $100M of FCF towards debt reduction annually
- Near-term debt leverage ratio target of 3.0x – 3.5x

Dividends and Share Repurchases
- Maintain current strategy
NEAR TERM OUTLOOK

- Full impact in Q1 and Q2 2017 of the October 2016 containerboard price increase
- $50/s.t. containerboard price increase announced for March 2017 in North America
- Higher average selling prices in all Groups
- Potential better demand in Europe
- FX still favourable (stable)

- Important increase in recovered paper prices in North America and Europe
- Lower seasonal volume in Tissue

<table>
<thead>
<tr>
<th>Q1-17 vs Q4-16</th>
<th>Boxboard Europe</th>
<th>EBITDA Impact</th>
<th>Containerboard</th>
<th>EBITDA Impact</th>
<th>Specialty Products</th>
<th>EBITDA Impact</th>
<th>Tissue Papers</th>
<th>EBITDA Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>Slight increase</td>
<td>↑</td>
<td>Stable</td>
<td>←</td>
<td>Slight increase</td>
<td>↑</td>
<td>Slight decrease</td>
<td>↓</td>
</tr>
<tr>
<td>Average selling prices</td>
<td>Slight increase</td>
<td>↑</td>
<td>Increase</td>
<td>↑</td>
<td>Slight increase</td>
<td>↑</td>
<td>Slight increase</td>
<td>↑</td>
</tr>
<tr>
<td>Raw material costs</td>
<td>Slight increase</td>
<td>↓</td>
<td>Increase</td>
<td>↓</td>
<td>Increase</td>
<td>↓</td>
<td>Slight increase</td>
<td>↓</td>
</tr>
<tr>
<td>CAN$ vs other currencies</td>
<td>Stable</td>
<td>←</td>
<td>Stable</td>
<td>←</td>
<td>Stable</td>
<td>←</td>
<td>Stable</td>
<td>←</td>
</tr>
<tr>
<td>Energy costs</td>
<td>Stable</td>
<td>←</td>
<td>Slight increase</td>
<td>↓</td>
<td>Stable</td>
<td>←</td>
<td>Slight increase</td>
<td>↓</td>
</tr>
</tbody>
</table>
APPENDIX
5-YEAR SHAREHOLDER RETURN
CAS vs. TSX Small Cap Index

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>TSX SCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Year</td>
<td>121%</td>
<td>137%</td>
</tr>
<tr>
<td>3 Year</td>
<td>175%</td>
<td>100%</td>
</tr>
<tr>
<td>5 Year</td>
<td>304%</td>
<td>99%</td>
</tr>
</tbody>
</table>

Note: Shareholder return excludes dividend yield. As of market close March 20, 2017.
### ILLUSTRATIVE SUM OF THE PARTS

<table>
<thead>
<tr>
<th>CAS 2016 adjusted EBITDA (Net of corp. activities)</th>
<th>CAS valuation using current analyst multiples</th>
<th>CAS valuation using 2018e average industry multiples</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Multiple</td>
<td>Value</td>
</tr>
<tr>
<td>Containerboard Packaging Group</td>
<td>216</td>
<td>5.6x</td>
</tr>
<tr>
<td>Boxboard Europe Group</td>
<td>53</td>
<td>4.2x</td>
</tr>
<tr>
<td>Specialty Products Group</td>
<td>65</td>
<td>5.3x</td>
</tr>
<tr>
<td>Tissue Papers Group</td>
<td>150</td>
<td>5.9x</td>
</tr>
<tr>
<td>Corporate Activities</td>
<td>(81)</td>
<td>5.5x</td>
</tr>
<tr>
<td><strong>Total Enterprise Value (and implied multiple)</strong></td>
<td>5.5x</td>
<td>2,217</td>
</tr>
</tbody>
</table>

| Add:                                               |                                                   |                                                   |
| JV contribution ($10M adj. EBITDA @ 6.0x)          | 60                                                 | 60                                               |

| Subtract:                                          |                                                   |                                                   |
| Net Debt @ December 31, 2016                      | (1,532)                                            | (1,532)                                          |

**Implied Equity Value - before adjustments**

- Add: Boralex stake (market value @ March 20, 2017) 273 $2.88 273 $2.88
- Add: Greenpac investment @ 8.0x, net of debt 238 $2.52 238 $2.52

- Subtract: Minority interest @ 4.2x, net of debt (62) ($0.66) (62) ($0.66)

**Implied Equity Value - after adjustments**

- 1,194 $12.60 1,912 $20.19

**Share Price @ March 20, 2017**

- $12.68 $12.68

**Implied share price upside potential**

- -1% 59%

---

2. 2018e average industry multiples applied for Containerboard Group and Tissue Papers Group only. Source: Bloomberg.

Comparable companies include: IP, KapStone, Packaging Corp. and WestRock for Containerboard; Clearwater, K-C, KP Tissue and Orchids Paper for Tissue Papers.
## HISTORICAL RESULTS

**(in millions of Canadian dollars)**

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>Q4-16</th>
<th>Q3-16</th>
<th>Q2-16</th>
<th>Q1-16</th>
<th>2015</th>
<th>Q4-15</th>
<th>Q3-15</th>
<th>Q2-15</th>
<th>Q1-15</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sales</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Containerboard</td>
<td>1,370</td>
<td>336</td>
<td>356</td>
<td>342</td>
<td>336</td>
<td>1,301</td>
<td>326</td>
<td>353</td>
<td>322</td>
<td>300</td>
<td>1,181</td>
</tr>
<tr>
<td>Boxboard Europe</td>
<td>796</td>
<td>191</td>
<td>189</td>
<td>197</td>
<td>219</td>
<td>825</td>
<td>202</td>
<td>205</td>
<td>202</td>
<td>216</td>
<td>841</td>
</tr>
<tr>
<td>Specialty Products</td>
<td>620</td>
<td>156</td>
<td>158</td>
<td>157</td>
<td>149</td>
<td>579</td>
<td>147</td>
<td>151</td>
<td>146</td>
<td>135</td>
<td>568</td>
</tr>
<tr>
<td>Tissue Papers</td>
<td>1,305</td>
<td>319</td>
<td>342</td>
<td>324</td>
<td>320</td>
<td>1,236</td>
<td>322</td>
<td>341</td>
<td>299</td>
<td>274</td>
<td>1,054</td>
</tr>
<tr>
<td>Inter-segment sales and corporate activities</td>
<td>(90)</td>
<td>(23)</td>
<td>(24)</td>
<td>(22)</td>
<td>(21)</td>
<td>(80)</td>
<td>(22)</td>
<td>(24)</td>
<td>(19)</td>
<td>(15)</td>
<td>(83)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>4,001</td>
<td>979</td>
<td>1,021</td>
<td>998</td>
<td>1,003</td>
<td>3,861</td>
<td>975</td>
<td>1,026</td>
<td>950</td>
<td>910</td>
<td>3,561</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Containerboard</td>
<td>216</td>
<td>43</td>
<td>58</td>
<td>60</td>
<td>55</td>
<td>231</td>
<td>56</td>
<td>68</td>
<td>55</td>
<td>52</td>
<td>164</td>
</tr>
<tr>
<td>Boxboard Europe</td>
<td>53</td>
<td>11</td>
<td>9</td>
<td>17</td>
<td>16</td>
<td>63</td>
<td>13</td>
<td>14</td>
<td>19</td>
<td>17</td>
<td>72</td>
</tr>
<tr>
<td>Specialty Products</td>
<td>65</td>
<td>17</td>
<td>18</td>
<td>16</td>
<td>14</td>
<td>58</td>
<td>16</td>
<td>18</td>
<td>14</td>
<td>10</td>
<td>40</td>
</tr>
<tr>
<td>Tissue Papers</td>
<td>150</td>
<td>30</td>
<td>47</td>
<td>39</td>
<td>34</td>
<td>119</td>
<td>38</td>
<td>43</td>
<td>23</td>
<td>15</td>
<td>96</td>
</tr>
<tr>
<td>Corporate activities</td>
<td>(81)</td>
<td>(19)</td>
<td>(29)</td>
<td>(20)</td>
<td>(13)</td>
<td>(45)</td>
<td>(19)</td>
<td>(9)</td>
<td>(8)</td>
<td>(9)</td>
<td>(32)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>403</td>
<td>82</td>
<td>103</td>
<td>112</td>
<td>106</td>
<td>426</td>
<td>104</td>
<td>134</td>
<td>103</td>
<td>85</td>
<td>340</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA Margin</strong></td>
<td><strong>10.1%</strong></td>
<td><strong>8.4%</strong></td>
<td><strong>10.1%</strong></td>
<td><strong>11.2%</strong></td>
<td><strong>10.6%</strong></td>
<td><strong>11.0%</strong></td>
<td><strong>10.7%</strong></td>
<td><strong>13.1%</strong></td>
<td><strong>10.8%</strong></td>
<td><strong>9.3%</strong></td>
<td><strong>9.5%</strong></td>
</tr>
</tbody>
</table>
GEOGRAPHICALLY DIVERSIFIED

NORTH AMERICA

ONTOHARIO

ONTARIO

QUEBEC

NORTHEASTERN UNITED STATES

EUROPE

LEGEND

- Head Office
- Containerboard Group
- Boxboard Europe Group
- Specialty Products Group
- Tissue Papers Group

- Manufacturing facility
- Converting facility
- Converting and manufacturing facility
- Recovery facility

GREEN BY NATURE™

For more information:
www.cascades.com/investors
Jennifer Aitken, MBA
Director, Investor Relations
514-282-2697 or jennifer_aitken@cascades.com